GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

initiated an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a dipeptidyl peptidase-4 (DPP-4) inhibitor as an alternative comparator. After inverse probability of ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Empagliflozin is a sodium-glucose contratransporter-2 inhibitor (SGLT-2), an oral medication ... Monitoring Committees for studies evaluating a GLP-1 receptor for Novo Nordisk.

GLP-1RAs and SGL2 inhibitors were associated with lower risks for NAFLD and NASH among patients with type 2 diabetes. Newer classes of glucose-lowering agents may reduce risk for liver disease among ...

In a target trial emulation including 20,146 patients with pre-existing nephrolithiasis and type 2 diabetes, including some with gout, the stone recurrence rate was lower among those taking SGLT2 ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

DOGE co-chair Elon Musk shocked his followers on Christmas Day by posting a tweet of his trimmed-down self in a Santa outfit.

The quest for effective weight loss solutions has never been more urgent, with millions of people worldwide struggling to ...

Elon Musk has revealed he has upgraded from Ozempic to Mounjaro, nicknamed the “King Kong” of weight-loss drugs, in a photo ...

The DPP-4 inhibitors represent the first oral therapies ... extending the physiologic half-life of endogenous GLP-1 and GIP by preventing their degradation. These agents are entirely dependent ...

The world’s richest man has clashed with incoming Health and Human Services chief Robert F. Kennedy Jr. over the role ...